Rallybio (RLYB)
(Delayed Data from NSDQ)
$0.55 USD
+0.02 (3.59%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.54 -0.01 (-1.46%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RLYB 0.55 +0.02(3.59%)
Will RLYB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RLYB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLYB
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
RLYB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
Other News for RLYB
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
Rallybio (RLYB) Shares Soar on Asset Sale to Recursion
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug